NTLA — Intellia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1652130 ·
Last close
$9.78
Market Cap
$1.37B
52W High
$18.48
52W Low
$7.95
ADV30
5,323,407
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 7,163,000 | — | -122,325,000 | -127,485,000 | 902,560,000 | 156,098,000 | 289,471,000 |
| Jun 2026 | 7,659,000 | — | -112,760,000 | -106,634,000 | 857,164,000 | 106,128,000 | 129,458,000 |
| Mar 2026 | 15,048,000 | — | -100,532,000 | -96,231,000 | 758,779,000 | 134,697,000 | 137,840,000 |
| Dec 2025 | 23,017,000 | — | -98,710,000 | -95,786,000 | 842,127,000 | 155,464,000 | 170,733,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-346,643,000
Investing CF
$-48,469,000
Financing CF
$346,519,000
CapEx
$-2,043,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.36
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,792,959,000
Inventory
—
Receivables
$7,321,000
ST Investments
$331,631,000
EBIT TTM
$-423,479,000
Pretax Income TTM
$-399,975,000
Interest Exp TTM
—
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$59,506,000
EBITDA
$-414,400,000
Free Cash Flow
$-249,825,376
Enterprise Value
$1,360,610,560
Total Cash
$437,759,008
Total Debt
$73,410,000
Shares Out
140,358,512
Trailing EPS
$-3.35
Book Value
$5.77
ROE
-55.4%
ROA
-30.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,671,000 | -440,990,000 | -412,694,000 | 842,127,000 | 170,733,000 | 671,394,000 | -394,736,000 |
| Dec 2024 | 57,877,000 | -534,263,000 | -519,021,000 | 1,191,015,000 | 319,059,000 | 871,956,000 | -348,880,000 |
| Dec 2023 | 36,275,000 | -515,291,000 | -481,192,000 | 1,300,977,000 | 250,808,000 | 1,050,169,000 | -394,086,000 |
| Dec 2022 | 52,121,000 | -458,164,000 | -474,186,000 | 1,520,114,000 | 284,530,000 | 1,235,584,000 | -333,287,000 |
TTM Snapshot
Revenues TTM
$59,506,000
NetIncome TTM
$-399,975,000
OpCashFlow TTM
—
Assets (Latest)
$857,164,000
Forward EPS
$-2.65
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.77 · call volume: 214 · put volume: 965
Expected Move to 2027-01-15:
±$2.34
(23.95%) —
implied range
$7.43 –
$12.11
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABSI | Absci Corp | $1.31B | $7.58 | — |
| CLDX | Celldex Therapeutics, Inc. | $2.20B | $28.04 | — |
| NEOG | NEOGEN CORP | $2.38B | $10.90 | — |
| OABI | OmniAb, Inc. | $736.59M | $5.05 | — |
| QDEL | QuidelOrtho Corp | $677.21M | $9.87 | — |
News headlines (Yahoo Finance, 1h cache)
Intellia Therapeutics (NTLA), Why Is It Back In The Spotlight?
2026-11-17 10:10 · Yahoo
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
2026-11-12 21:14 · Yahoo
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
2026-11-12 15:00 · Yahoo
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
2026-11-10 13:00 · Yahoo
Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress
2026-11-07 05:20 · Yahoo
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:05 · Yahoo
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 13:35 · Yahoo
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
2026-11-05 13:00 · Yahoo
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
2026-11-04 13:00 · Yahoo
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
2026-11-03 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.